These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27721413)

  • 21. Beta-peptides with improved affinity for hDM2 and hDMX.
    Harker EA; Daniels DS; Guarracino DA; Schepartz A
    Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.
    Meulmeester E; Maurice MM; Boutell C; Teunisse AF; Ovaa H; Abraham TE; Dirks RW; Jochemsen AG
    Mol Cell; 2005 May; 18(5):565-76. PubMed ID: 15916963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
    Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P
    ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
    Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
    J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HdmX overexpression inhibits oncogene induced cellular senescence.
    Miller KR; Kelley K; Tuttle R; Berberich SJ
    Cell Cycle; 2010 Aug; 9(16):3376-82. PubMed ID: 20724842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hdmx modulates the outcome of p53 activation in human tumor cells.
    Wade M; Wong ET; Tang M; Stommel JM; Wahl GM
    J Biol Chem; 2006 Nov; 281(44):33036-44. PubMed ID: 16905769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further insight into substrate recognition by USP7: structural and biochemical analysis of the HdmX and Hdm2 interactions with USP7.
    Sarkari F; La Delfa A; Arrowsmith CH; Frappier L; Sheng Y; Saridakis V
    J Mol Biol; 2010 Oct; 402(5):825-37. PubMed ID: 20713061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation.
    Migliorini D; Danovi D; Colombo E; Carbone R; Pelicci PG; Marine JC
    J Biol Chem; 2002 Mar; 277(9):7318-23. PubMed ID: 11744695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of linker on the binding free energy of stapled p53/HDM2 complex.
    Im H; Ham S
    PLoS One; 2020; 15(4):e0232613. PubMed ID: 32353067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
    Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
    J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of the hdm2-p53 interaction.
    Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
    J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism.
    Calderon-González KG; Medina-Medina I; Haronikova L; Hernychova L; Bonczek O; Uhrik L; Hrabal V; Vojtesek B; Fahraeus R; Hernández-Monge J; Olivares-Illana V
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35674210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays.
    Tan BX; Brown CJ; Ferrer FJ; Yuen TY; Quah ST; Chan BH; Jansson AE; Teo HL; Nordlund P; Lane DP
    Sci Rep; 2015 Jul; 5():12116. PubMed ID: 26159518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling.
    Berberich SJ
    Cell Cycle; 2010 Sep; 9(18):3640-1. PubMed ID: 20855947
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
    Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
    Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the p53-hdm2 interaction with low molecular weight compounds.
    Chène P
    Cell Cycle; 2004 Apr; 3(4):460-1. PubMed ID: 14976429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.